Trial
NCT00575016
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Allergan
Collaborators
—
Condition
Overactive Bladder
Intervention
Normal saline (Placebo)
Why stopped
The study was terminated early due to enrollment challenges.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-10-02